For Clinicians
Numerous published studies—spanning more than 36,000
patients—have demonstrated that the level of ST2 in blood can predict chronic
heart failure patient outcomes.
Measuring ST2 via a simple, non-invasive blood test allows
for the early identification of chronic heart failure patients at highest risk
for re-hospitalization and mortality versus those at lower risk.
ST2 levels change rapidly in response to changes in the
patient’s condition, and when used in conduction with other clinical
parameters, helping you to focus on patients requiring immediate medical
attention.
ST2 levels are not adversely affected by such factors as
age, gender, BMI, atrial fibrillation, history of heart failure, anemia, and
impaired renal function.
ST2 has a single cutpoint, removing any guesswork, making
treatment decisions easier.
There are several ways in which results from ST2 testing
can be useful in chronic heart failure patient management including:
Focused Outpatient Care
Focused planning for heart failure patients can reduce
costly hospital readmissions.
Unlike many other cardiac biomarkers, ST2 levels change
quickly and signficantly in response to changes in the patient’s condition—thus
helping physicians make informed decisions on an appropriate course of action
to take, and if needed, to quickly adjust care, improving patient outcomes and
optimizing the interval between patient visits.
Clinicians that use ST2 as part of a patient management
program can potentially impact 30-day rehospitalization and mortality rates for
patients with chronic heart failure.
Assessing Referrals
ST2 can be used to assess which patients are at highest
risk for adverse events and therefore should be referred to a specialist.
If You’re Interested in
Conducting A Clinical Trial Involving ST2
To find out about purchasing purchasing kits for a
clinical study, please contact us at info@criticaldiagnostics.com or call
877.700.1250.